Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a met...
Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
About this item
Full title
Author / Creator
Publisher
New Zealand: Dove Medical Press Limited
Journal title
Language
English
Formats
Publication information
Publisher
New Zealand: Dove Medical Press Limited
Subjects
More information
Scope and Contents
Contents
The purpose of this study was to compare the efficacy and safety of brexpiprazole 4 mg/day (B4) and 2 mg/day (B2) for treating acute schizophrenia.
We performed three categorical meta-analyses (B4 vs placebo, B2 vs placebo, and B4 vs B2) of double-blind, randomized placebo-controlled trials (DBRCTs) that reported improvements in the Positive and...
Alternative Titles
Full title
Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6171755
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6171755
Other Identifiers
ISSN
1178-2021,1176-6328
E-ISSN
1178-2021
DOI
10.2147/NDT.S176676
